WuXi Clinical Development Services Expands Use of Medidata’s Cloud Technology Platform

NEW YORK–(BUSINESS WIRE)– Medidata
(NASDAQ:MDSO), the leading global provider of cloud-based solutions for
clinical research in life sciences, today announced an expanded
partnership with WuXi
Clinical Development Services (“WuXi CDS”), a wholly-owned
subsidiary of the global pharmaceutical, biopharmaceutical and medical
device open-access capability and technology platform company, WuXi
AppTec.

WuXi CDS is standardizing on the Medidata
Clinical Cloud^® to enhance its capabilities in
early-phase and bioequivalence (BE) studies, bringing operational
efficiencies to its customers’ clinical development programs across the
country.

“WuXi CDS’ strengthened partnership with Medidata reinforces our
commitment to advancing the scientific goals of our customers—both big
and small, global and local,” said Mr. Jinjin Liang, Vice President,
Head of WuXi Clinical Development Services. “Medidata’s agile,
globally-validated platform is enabling our study teams to conduct
insightful and value-driven clinical research in a timely
manner—ultimately helping us serve the needs of our clients to bring
innovative, breakthrough products to the Chinese market. We’re excited
about taking our R&D programs to the next level, and look forward to
entering a long-term strategic relationship with Medidata.”

WuXi CDS offers comprehensive Phase I–IV clinical development services
for pharmaceutical, biologic and medical devices companies in China and
abroad. In increasing its adoption of Medidata
Rave^®, the industry’s leading cloud-based technology for
electronic data capture (EDC), management and reporting, WuXi will
provide more flexible, customized strategic solutions to advance the
development of new therapies across a number of therapeutic areas,
including: oncology, immunology, infectious diseases, respiratory,
gastroenterology, hematology, cardio-metabolic, dermatology and
gynecology. WuXi has also recently become accredited in Medidata’s
randomization and trial supply management solution (Medidata
Balance^®), which it is leveraging on an increasing number
of domestic studies.

“We are thrilled to be working with WuXi CDS, a company that is uniquely
positioned to bring highly specialized clinical expertise and deep local
knowledge to both the global and Chinese market,” said Edwin Ng,
Medidata’s vice president of field operations, APeJ (Asia Pacific except
Japan). “At Medidata, we share WuXi CDS’ vision of conducting high
quality clinical research, and we’re proud that our robust, cutting-edge
technology is playing a key role in supporting the organization’s strong
portfolio of clinical studies for today’s most prevalent illnesses.”

Mike Capone, Medidata’s chief operating officer, added: “Medidata is
proudly working with more than 100 CROs, as well as services, consulting
and technical partners, to help sponsors realize the value and powerful
new insights that technology and data analytics can bring to their
clinical trials. WuXi is a market leader and a strong agent of change
for the global life sciences industry, and we’re committed to further
supporting the team’s efforts to accelerate promising new drug
compounds, biologics and medical devices for its clients and their
patients everywhere.”

Connect with Medidata

• Read our blog, Geeks
  Talk Clinical
• Tweet this: .@WuXi_AppTec
  #ClinicalDevelopment Services selects #MedidataRave for streamlined
  #datacapture & study ops http://ow.ly/DEOj30b7WHZ @Medidata
• Follow us on Twitter: @Medidata
• Find us on LinkedIn

About WuXi Clinical Development Services

WuXi
Clinical Development Services is a wholly-owned subsidiary of WuXi
AppTec in China. The company offers comprehensive Phase I – IV clinical
development services for pharmaceuticals, biologics, and medical
devices. WuXi CDS specializes in helping bring innovative, breakthrough
products to market – a process that demands stringent quality control
and experienced professionals from Phase I through to final submission.

WuXi CDS also offers flexible, customized strategic solutions –
professionals who deliver services right from the clients’ offices,
supporting specific tasks or helping ride out the peaks and troughs
inherent in clinical development project timelines.

About Medidata

Medidata
is reinventing global drug and medical device development by creating
the industry’s leading cloud-based solutions for clinical research.
Through our advanced applications and intelligent data analytics,
Medidata helps advance the scientific goals of life sciences customers
worldwide, including nearly 850 global pharmaceutical companies,
biotech, diagnostic and device firms, leading academic medical centers,
and contract research organizations.

The Medidata Clinical Cloud^® brings a new level of quality
and efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled clinical
trial data assets provide deep insights that pave the way for future
growth. The Medidata Clinical Cloud is the primary technology solution
powering clinical trials for 17 of the world’s top 25 global
pharmaceutical companies and is used by 16 of the top 20 medical device
developers—from study design and planning through execution, management
and reporting.

Image may be NSFW.
Clik here to view.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170424006578/en/